Show simple item record

dc.creatorBall, D.
dc.date.accessioned2017-06-28T10:17:27Z
dc.date.accessioned2019-05-28T14:36:48Z
dc.date.available2017-06-28T10:17:27Z
dc.date.available2019-05-28T14:36:48Z
dc.date.created2017-06-28T10:17:27Z
dc.date.issued2000
dc.identifierBall, D. (2000). An overview of spontaneous reporting of adverse drug reactions (ARDs) in Zimbabwe. Central African Journal of Medicine, 46 (1), 23-24.
dc.identifier0008-9176
dc.identifierhttp://hdl.handle.net/10646/3302
dc.identifier.urihttp://zdhr.uz.ac.zw/xmlui/handle/123456789/1308
dc.description.abstractThe deaths of over 100 people in 1937 in the USA from the ingestion of antifreeze used as a solvent for sulfanilamide and the foetal malformations of thalidomide in Europe in the 1960s resulted in the development of drug regulatory agencies as we know them today.1 These authorities licence medicines for the market using the criteria of safety, efficacy and quality. However, clinical trials are inefficient at determining safety since they involve relatively few, selected patients in controlled prescribing environments. It is necessary to monitor marketed medicines for safety under normal prescribing. This is post marketing surveillance or pharmacovigilance. Various systems are available ranging from compulsory reporting of adverse drug reactions (ADRs) through intensive hospital monitoring to spontaneous voluntary reporting.2 The latter, is more common since it is inexpensive and easy to* * implement whilst being useful in identifying uncommon ADRs.
dc.languageen_ZW
dc.publisherUniversity of Zimbabwe, College of Health Sciences
dc.subjectDrug reaction
dc.titleAn overview of spontaneous reporting of adverse drug reactions (ARDs) in Zimbabwe
dc.typeArticle


Files in this item

FilesSizeFormatView
Ball_An_overview_of_spantaneous_reporting.pdf76.49Kbapplication/pdfView/Open

This item appears in the following Collection(s)

Show simple item record